

Edgar Filing: PHARMION CORP - Form 8-K

PHARMION CORP
Form 8-K
June 04, 2007

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) June 4, 2007

Pharmion Corporation

(Exact name of registrant as specified in its charter)

Delaware

000-50447

84-1521333

(State or other jurisdiction
of incorporation)

(Commission File
Number)

(IRS Employer
Identification No.)

2525 28th Street, Boulder, Colorado

80301

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code 720-564-9100

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

- Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
-

Edgar Filing: PHARMION CORP - Form 8-K

Item 8.01 Other Events.

On June 4, 2007, Pharmion Corporation (the "Company") announced clinical data from various studies investigating the Company's marketed and pipeline products as presented at the American Society of Clinical Oncology's 43rd Annual Meeting.

The press releases are filed as Exhibits 99.1 and 99.2 to this Form 8-K and are incorporated herein by reference in their entirety.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release issued by Pharmion Corporation on June 4, 2007 announcing Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial.

99.2 Press Release issued by Pharmion Corporation on June 4, 2007 announcing Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer.

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMION CORPORATION

Date: June 4, 2007

By: /s/ Steven N. Dupont

Name: Steven N. Dupont

Title: Vice President and General Counsel

- 3 -